Ally Bridge Group (Ny) LLC Trevi Therapeutics, Inc. Transaction History
Ally Bridge Group (Ny) LLC
- $76.1 Million
- Q1 2025
A detailed history of Ally Bridge Group (Ny) LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Ally Bridge Group (Ny) LLC holds 686,219 shares of TRVI stock, worth $5.09 Million. This represents 5.67% of its overall portfolio holdings.
Number of Shares
686,219
Previous 781,489
12.19%
Holding current value
$5.09 Million
Previous $3.33 Million
29.65%
% of portfolio
5.67%
Previous 3.78%
Shares
4 transactions
Others Institutions Holding TRVI
# of Institutions
151Shares Held
85.6MCall Options Held
1.51MPut Options Held
304K-
Nea Management Company, LLC Timonium, MD11.4MShares$84.4 Million6.78% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$76.1 Million4.06% of portfolio
-
Rubric Capital Management LP New York, NY4.54MShares$33.7 Million0.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.84MShares$28.5 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.49MShares$25.9 Million5.95% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $433M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...